| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1373384 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
A new class of selective NPS antagonist was developed starting from a commercially available product identified by screening activities. Experimental NMR observations and computational experiments allowed the discovery of a new class of derivatives. 5-Phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-one represents a new lead compound in the NPS antagonist field.
Graphical abstractA new lead series was identified in the NPS antagonist field. The compound was prepared following up experimental observations rationalized with computational chemistry techniques and rational design.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Fabrizio Micheli, Romano Di Fabio, Angelo Giacometti, Adelheid Roth, Elisa Moro, Giancarlo Merlo, Alfredo Paio, Emilio Merlo-Pich, Silvia Tomelleri, Federica Tonelli, Paola Zarantonello, Laura Zonzini, Anna Maria Capelli,
![First Page Preview: Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: A new class of Neuropeptide S antagonists Synthesis and pharmacological characterization of 5-phenyl-2-[2-(1-piperidinylcarbonyl)phenyl]-2,3-dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones: A new class of Neuropeptide S antagonists](/preview/png/1373384.png)